share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外国发行人报告
美股sec公告 ·  05/14 09:04
Moomoo AI 已提取核心信息
On May 14, 2024, NeuroSense Therapeutics announced a partnership with PhaseV to enhance the upcoming Phase 3 trial of PrimeC for ALS treatment using advanced causal machine learning. PhaseV's analysis of NeuroSense's Phase 2b PARADIGM study predicts a high probability of success in multiple ALS subgroups for the Phase 3 trial. The insights gained will inform study design and patient enrollment, aiming to maximize clinical results and market differentiation for PrimeC. NeuroSense recently reported positive results from the PARADIGM trial, showing a significant slowing in disease progression, and plans to submit its End of Phase 2 package to the FDA and EMA soon. PhaseV's technology aids in optimizing clinical trial design by identifying likely successful subgroups and endpoints. NeuroSense focuses on developing treatments for neurodegenerative diseases, with a primary focus on ALS.
On May 14, 2024, NeuroSense Therapeutics announced a partnership with PhaseV to enhance the upcoming Phase 3 trial of PrimeC for ALS treatment using advanced causal machine learning. PhaseV's analysis of NeuroSense's Phase 2b PARADIGM study predicts a high probability of success in multiple ALS subgroups for the Phase 3 trial. The insights gained will inform study design and patient enrollment, aiming to maximize clinical results and market differentiation for PrimeC. NeuroSense recently reported positive results from the PARADIGM trial, showing a significant slowing in disease progression, and plans to submit its End of Phase 2 package to the FDA and EMA soon. PhaseV's technology aids in optimizing clinical trial design by identifying likely successful subgroups and endpoints. NeuroSense focuses on developing treatments for neurodegenerative diseases, with a primary focus on ALS.
2024年5月14日，NeuroSense Therapeutics宣布与PhasEV建立合作伙伴关系，以加强即将进行的使用高级因果机器学习进行肌萎缩性侧索硬化症治疗的PrimeC的3期试验。PhaseV对NeuroSense的2b期PARADIGM研究的分析预测，在3期试验的多个肌萎缩性侧索硬化症亚组中，成功的可能性很高。获得的见解将为研究设计和患者入组提供信息，旨在最大限度地提高PrimeC的临床结果和市场差异化。NeuroSense最近报告了PARADIGM试验的积极结果，显示疾病进展显著放缓，并计划尽快向美国食品药品管理局和欧洲药品管理局提交其第二阶段结束套餐。PhaseV的技术通过识别可能成功的子组和终点来帮助优化临床试验设计。NeuroSense专注于开发神经退行性疾病的治疗方法，主要关注肌萎缩性侧索硬化症。
2024年5月14日，NeuroSense Therapeutics宣布与PhasEV建立合作伙伴关系，以加强即将进行的使用高级因果机器学习进行肌萎缩性侧索硬化症治疗的PrimeC的3期试验。PhaseV对NeuroSense的2b期PARADIGM研究的分析预测，在3期试验的多个肌萎缩性侧索硬化症亚组中，成功的可能性很高。获得的见解将为研究设计和患者入组提供信息，旨在最大限度地提高PrimeC的临床结果和市场差异化。NeuroSense最近报告了PARADIGM试验的积极结果，显示疾病进展显著放缓，并计划尽快向美国食品药品管理局和欧洲药品管理局提交其第二阶段结束套餐。PhaseV的技术通过识别可能成功的子组和终点来帮助优化临床试验设计。NeuroSense专注于开发神经退行性疾病的治疗方法，主要关注肌萎缩性侧索硬化症。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息